Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


King Lowers Sonata Forecast, Citing Increased Competitive Activity

This article was originally published in The Pink Sheet Daily

Executive Summary

King takes $126.9 mil. charge in the second quarter related to Sonata; quarterly sales of the sleep aid are up due to inventory reductions.

You may also be interested in...

Reductions In King Wholesale Inventory Drive Q2 Branded Pharma Sales

King Pharmaceuticals is attributing a rebound in branded pharmaceutical sales during the second quarter in part to lower wholesaler inventories

Takeda's Rozerem To Launch In September Following FDA Approval

Ramelteon clears FDA for "treatment of insomnia characterized by difficulty with sleep onset." Takeda is positioning Rozerem as the only prescription insomnia agent that does not carry controlled substance scheduling.

King Sonata DTC Campaign To Highlight Middle-Of-Night Dosing

The company seeks to exploit the benefit of middle-of-the-night dosing for zaleplon through a direct-to-consumer campaign. Ads for Sepracor's Lunesta and Sanofi-Aventis' Ambien will help grow the insomnia category rather than take share away from Sonata, King exec predicts.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts